Use of ACE inhibitors in Serbia in 2010 by unknown
MEETING ABSTRACT Open Access
Use of ACE inhibitors in Serbia in 2010
Boris Milijašević*, Zdenko Tomić, Ana Sabo, Aleksandar Rašković, Momir Mikov
From 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint meeting with the
Croatian, Serbian and Slovenian Pharmacological Societies.
Graz, Austria. 20-21 September 2012
Background
Cardiovascular diseases are the most frequent cause of
morbidity and mortality in many countries. That
explains why medications for the treatment of cardio-
vascular diseases are the group of drugs with the largest
consumption, and ACE inhibitors take a large part in
this consumption. The aim of this study was to analyze
the consumption of ACE inhibitors in Serbia in 2010
compared with Norway, a country with a developed
pharmacotherapeutic practice.
Methods
The data about the use of ACE inhibitors in Serbia were
taken from the Agency for Drugs and Medical Devices of
the Serbia. The data about drug consumption in Norway
were taken from the official website of the Norwegian
Institute of Public Health.
Results
In Serbia, the use of drugs of first choice in the treatment
of hypertension was very uneven, where the consumption
of ACE inhibitors was dominant. Opposed to this condi-
tion, the consumption of the first choice antihypertensive
drugs was very balanced in Norway. Total consumption of
ACE inhibitors in Serbia in 2010 year was 190.4 defined
daily doses per 1000 inhabitants per day (DID) and total
consumption of ACE inhibitors in Norway in 2010 year
was 51.7 DID. During the analyzed year the largest use of
plain ACE inhibitors in Serbia was for enalapril (81.0
DID), ramipril (34.2 DID), fosinopril (24.5 DID) and cila-
zapril (13.1 DID) and in Norway was ramipril (27.3 DID),
enalapril (11.1 DID) and lisinopril (6.2 DID). In Serbia a
significant part of the consumption of ACE inhibitors con-
sisted of more expensive drugs such as fosinopril, cilazapril
and quinapril, whereas these have not been used at all in
Norway during that period.
Conclusions
In Serbia in the year 2010, ACE inhibitors and their fixed
combination with diuretics are the most frequently used
drugs within the group of drugs which is used for cardio-
vascular diseases treatment. The amount and structure of
the utilized ACE inhibitors in Serbia is different in a lot of
ways from the amount and structure of the utilized ACE
inhibitors in Norway. Pharmacoeconomic analyses also
show that large financial resources would be saved if the
structure of the utilized ACE inhibitors in Serbia were
more similar to the one in Norway.
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